GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Castle Biosciences Inc (NAS:CSTL) » Definitions » Gross Profit

Castle Biosciences (Castle Biosciences) Gross Profit : $174.8 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Castle Biosciences Gross Profit?

Castle Biosciences's gross profit for the three months ended in Dec. 2023 was $53.7 Mil. Castle Biosciences's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $174.8 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Castle Biosciences's gross profit for the three months ended in Dec. 2023 was $53.7 Mil. Castle Biosciences's Revenue for the three months ended in Dec. 2023 was $66.1 Mil. Therefore, Castle Biosciences's Gross Margin % for the quarter that ended in Dec. 2023 was 81.21%.

Castle Biosciences had a gross margin of 81.21% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 7 years, the highest Gross Margin % of Castle Biosciences was 85.91%. The lowest was 64.21%. And the median was 79.53%.


Castle Biosciences Gross Profit Historical Data

The historical data trend for Castle Biosciences's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Castle Biosciences Gross Profit Chart

Castle Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial 44.56 52.96 78.26 105.03 174.81

Castle Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.82 31.86 39.08 50.17 53.70

Competitive Comparison of Castle Biosciences's Gross Profit

For the Diagnostics & Research subindustry, Castle Biosciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Castle Biosciences's Gross Profit Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Gross Profit distribution charts can be found below:

* The bar in red indicates where Castle Biosciences's Gross Profit falls into.



Castle Biosciences Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Castle Biosciences's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=219.788 - 44.982
=174.8

Castle Biosciences's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=66.12 - 12.423
=53.7

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $174.8 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Castle Biosciences's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=53.7 / 66.12
=81.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Castle Biosciences  (NAS:CSTL) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Castle Biosciences had a gross margin of 81.21% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Castle Biosciences Gross Profit Related Terms

Thank you for viewing the detailed overview of Castle Biosciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Castle Biosciences (Castle Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
505 S. Friendswood Drive, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Executives
Daniel Bradbury director BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Derek J Maetzold director, 10 percent owner, officer: Pres. & Chief Exec. Officer 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Ellen Goldberg director C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Tiffany Olson director C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Kristen M Oelschlager officer: Chief Operating Officer C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Bernhard E. Spiess officer: Chief Operating Officer C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Kim Caple director C/O BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Frank Stokes officer: Chief Financial Officer C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Tobin W Juvenal officer: Chief Commercial Officer C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
David S Kabakoff director, 10 percent owner C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Cook Joseph C. Iii director, 10 percent owner C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, STE. 201, FRIENDSWOOD TX 77546
Mara G. Aspinall director 7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Bonnie H Anderson director 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mgc Venture Partners 2013 Gp, Llc 10 percent owner C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203
Mgc Venture Partners 2013, L.p. 10 percent owner C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203

Castle Biosciences (Castle Biosciences) Headlines

From GuruFocus